Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MRNA |
---|---|---|
09:32 ET | 145734 | 63.3099 |
09:34 ET | 30056 | 63.2733 |
09:36 ET | 30339 | 63.3551 |
09:38 ET | 14896 | 63.4699 |
09:39 ET | 31299 | 63.0501 |
09:41 ET | 33749 | 62.97 |
09:43 ET | 20436 | 62.82 |
09:45 ET | 34832 | 62.8 |
09:48 ET | 27368 | 62.77 |
09:50 ET | 19557 | 62.86 |
09:52 ET | 53024 | 63.17 |
09:54 ET | 15054 | 63.08 |
09:56 ET | 14195 | 63.015 |
09:57 ET | 25558 | 62.975 |
09:59 ET | 13834 | 62.87 |
10:01 ET | 8398 | 62.905 |
10:03 ET | 12144 | 63.23 |
10:06 ET | 31310 | 63.15 |
10:08 ET | 15930 | 63.0986 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Moderna Inc | 24.6B | -4.1x | --- |
ICON PLC | 23.6B | 34.0x | +4.68% |
Biontech SE | 28.5B | -51.0x | --- |
Biogen Inc | 27.8B | 24.1x | -18.14% |
Grifols SA | 7.0B | 35.9x | --- |
Beigene Ltd | 26.5B | -45.2x | --- |
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.6B |
---|---|
Revenue (TTM) | $5.1B |
Shares Outstanding | 384.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.67 |
EPS | $-15.37 |
Book Value | $36.27 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | 4.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -91.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.